Researchers find new indication for cancer drugFrench researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma. more ➔
Research team improves safety of LGMD2A gene therapyResearchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer. more ➔
€7.34m for cancer vaccine developer Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes. more ➔
GeNeuro and Karolinska Institute collaborate in multiple sclerosisGeneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC. more ➔
Tecentriq-Avastin combo hits endpoint in liver cancerRoche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patien … more ➔
Azeria Therapeutics bags €37.3m in Series B financing roundAzeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (€37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (€34.4m). more ➔
GHO capital launches EU’s largest fund ever for life sciencesGHO Capital raises €975m in largest ever European private equity healthcare fund. more ➔
Update: BIO-Europe growing furtherEurope’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg. more ➔
Zelluna Immunotherapy and Glycostem Therapeutics in licence dealZelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies. more ➔
Novo secures Dicerna’s RNAi liver assetsDanish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets. more ➔
